---
document_datetime: 2025-12-29 07:37:41
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sumatriptan-galpharm.html
document_name: sumatriptan-galpharm.html
version: success
processing_time: 0.0616976
conversion_datetime: 2025-12-31 01:46:49.573908
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sumatriptan Galpharm

[RSS](/en/individual-human-medicine.xml/65768)

##### Refused

This medicine has been refused authorisation

sumatriptan Medicine Human Refused

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product details](#product-details)
- [Application details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 21 July 2011, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Sumatriptan Galpharm, intended for the relief of migraine attacks in people who have been diagnosed with migraine. The company that applied for authorisation is Galpharm Healthcare Ltd. The applicant requested a re-examination of the negative opinion. After considering the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the refusal of the marketing authorisation on 17 November 2011.

Questions and answers on the refusal of the marketing authorisation for Sumatriptan Galpharm 50 mg tablets - Outcome of re-examination

Adopted

Reference Number: EMA/CHMP/896315/2011

English (EN) (54.15 KB - PDF)

**First published:** 18/11/2011

**Last updated:** 18/11/2011

[View](/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_en.pdf)

[Other languages (21)](#file-language-dropdown-280)

български (BG) (84.66 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_bg.pdf)

español (ES) (48.2 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_es.pdf)

čeština (CS) (74.44 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_cs.pdf)

dansk (DA) (47.93 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_da.pdf)

Deutsch (DE) (47.89 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_de.pdf)

eesti keel (ET) (66.4 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_et.pdf)

ελληνικά (EL) (85.8 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_el.pdf)

français (FR) (48.17 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_fr.pdf)

italiano (IT) (49.58 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_it.pdf)

latviešu valoda (LV) (74.26 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_lv.pdf)

lietuvių kalba (LT) (73.08 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_lt.pdf)

magyar (HU) (68.17 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_hu.pdf)

Malti (MT) (73.39 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_mt.pdf)

Nederlands (NL) (46.72 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_nl.pdf)

polski (PL) (73.44 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_pl.pdf)

português (PT) (53.74 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_pt.pdf)

română (RO) (73.08 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_ro.pdf)

slovenčina (SK) (72.56 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_sk.pdf)

slovenščina (SL) (129.05 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_sl.pdf)

Suomi (FI) (48.65 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_fi.pdf)

svenska (SV) (46.97 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_sv.pdf)

## Product details

Name of medicine Sumatriptan Galpharm Active substance sumatriptan succinate International non-proprietary name (INN) or common name sumatriptan Therapeutic area (MeSH) Migraine Disorders

## Application details

EMA product number EMEA/H/C/002140

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation applicant Galpharm Healthcare Ltd. Opinion adopted 17/11/2011 Refusal of marketing authorisation 09/02/2012

## Assessment history

Sumatriptan Galpharm : EPAR - Public assessment report

Adopted

Reference Number: EMA/40740/2012

English (EN) (351.11 KB - PDF)

**First published:** 16/02/2012

**Last updated:** 16/02/2012

[View](/en/documents/assessment-report/sumatriptan-galpharm-epar-public-assessment-report_en.pdf)

**This page was last updated on** 16/02/2012

## Share this page

[Back to top](#main-content)